Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence.

D. Price | A. Sheikh | H. Schünemann | E. Novellino | L. Boulet | J. Bousquet | T. Zuberbier | C. Bachert | J. Brożek | T. Casale | K. Ohta | Á. Cruz | W. Fokkens | J. Fonseca | T. Haahtela | O. Kalayci | M. Kowalski | J. Mullol | R. O’Hehir | D. Ryan | B. Samoliński | E. Valovirta | A. Yorgancioglu | I. Agache | J. Bouchard | P. Kuna | Y. Okamoto | G. Scadding | A. Muraro | A. Bedbrook | K. Bergmann | S. Bosnic-Anticevich | L. Klimek | V. Kvedarienė | A. Valiulis | P. Devillier | P. Hellings | M. Calderón | K. L. Lødrup Carlsen | G. Passalacqua | S. Walker | M. Bewick | G. Roberts | S. Halken | M. Jutel | S. Lau | O. Pfaar | D. Laune | N. Roche | P. Panzner | P. Lieberman | P. Carreiro-Martins | G. D'Amato | L. Cecchi | M. Ebisawa | G. Brusselle | L. Caraballo | S. La Grutta | N. Rosário | M. Sanchez‐Borges | I. Ansotegui | D. Chu | T. Iinuma | A. Togias | M. Shamji | B. Gemicioğlu | S. Waserman | G. Mercier | M. Khaitov | Hae‐Sim Park | V. Cardona | M. Ventura | D. Ierodiakonou | E. Menditto | D. Wallace | R. V. van Wijk | W. Canonica | E. Mélen | C. Rolland | H. Neffen | P. Bonniaud | M. Dykewicz | W. Czarlewski | J. Ivancevich | S. Toppila-Salmi | E. Costa | M. Valentín-Rostán | Martina Erhola | I. Bossé | J. Fauquert | J. Fontaine | I. Kaidashev | Jörg Kleine Tebbe | Désirée Larenas‐Linemann | L. Le | O. Lourenço | G. Marien | Ralph Mosgues | L. Namazova | N. Pham-Thi | A. T. Bom | I. Tsiligianni | N. Pham‐Thi | R. O'Hehir | P. Carreiro‐Martins | Ioana Tsiligianni | A. Sheikh | J. Bousquet | M. Sánchez-Borges | Jean-Louis Fauquert

[1]  F. Tarazona-Santabalbina,et al.  Enfermedad por coronavirus 2019 (COVID-19) y edadismo: revisión narrativa de la literatura , 2020, Revista Española de Geriatría y Gerontología.

[2]  J. Bousquet,et al.  Mobile health tools for the management of chronic respiratory diseases , 2019, Allergy.

[3]  A. Sheikh,et al.  Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. , 2019, The Journal of allergy and clinical immunology.

[4]  A. Togias,et al.  Clinical standardization of two controlled allergen challenge facilities: The Environmental Exposure Unit and the Biogenics Research Chamber. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  A. Sheikh,et al.  Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study , 2019, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  O. Mayora,et al.  Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma , 2019, Clinical and Translational Allergy.

[7]  A. Sheikh,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. , 2019, The Journal of allergy and clinical immunology.

[8]  D. Jalal,et al.  Resistant Hypertension: Diagnosis and Management. , 2019, Advances in chronic kidney disease.

[9]  Rosalind W. Picard,et al.  MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence , 2018, Clinical and Translational Allergy.

[10]  A. Millier,et al.  Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations , 2018, Current medical research and opinion.

[11]  Daniel Laune,et al.  POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project , 2018, Clinical and Translational Allergy.

[12]  A. Sheikh,et al.  Treatment of allergic rhinitis using mobile technology with real‐world data: The MASK observational pilot study , 2018, Allergy.

[13]  J. Bousquet,et al.  Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. , 2018, The journal of allergy and clinical immunology. In practice.

[14]  Boleslaw Samolinski,et al.  Electronic Clinical Decision Support System for allergic rhinitis management: MASK e‐CDSS , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  A. Sheikh,et al.  Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study , 2018, Allergy.

[16]  J. Bousquet,et al.  The allergic allergist behaves like a patient. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  P. Ribó,et al.  Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort , 2018, Clinical and Translational Allergy.

[18]  A. Sheikh,et al.  The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study , 2018, Allergy.

[19]  O. Mayora,et al.  Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA‐ARIA) ‐ EIP on AHA Twinning Reference Site (GARD research demonstration project) , 2018, Allergy.

[20]  J. Bousquet,et al.  European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017) , 2017, Clinical and Translational Allergy.

[21]  E. Meltzer,et al.  Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[22]  P. Cullinan,et al.  Impact of Rhinitis on Work Productivity: A Systematic Review. , 2017, The journal of allergy and clinical immunology. In practice.

[23]  Joaquim Mullol,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision , 2017, The Journal of allergy and clinical immunology.

[24]  O. Mayora,et al.  Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  A. Sheikh,et al.  The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. , 2017, Journal of investigational allergology & clinical immunology.

[26]  T. Zuberbier,et al.  Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper , 2017, Allergy.

[27]  P Demoly,et al.  Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK‐rhinitis study , 2017, Allergy.

[28]  A. Sheikh,et al.  Realising the potential of mHealth to improve asthma and allergy care: how to shape the future , 2017, European Respiratory Journal.

[29]  Ludger Klimek,et al.  Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care , 2017, Allergo Journal International.

[30]  Todor A Popov,et al.  ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle , 2016, Clinical and Translational Allergy.

[31]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[32]  Todor A Popov,et al.  MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. , 2016, The Journal of allergy and clinical immunology.

[33]  Antonis A. Kousoulis,et al.  Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances , 2016, BMC Health Services Research.

[34]  Tricia A. Miller,et al.  Health literacy and adherence to medical treatment in chronic and acute illness: A meta-analysis. , 2016, Patient education and counseling.

[35]  E. Meltzer,et al.  Minimal Clinically Important Difference (MCID) in Allergic Rhinitis: Agency for Healthcare Research and Quality or Anchor-Based Thresholds? , 2016, The journal of allergy and clinical immunology. In practice.

[36]  R W Batterham,et al.  Health literacy: applying current concepts to improve health services and reduce health inequalities. , 2016, Public health.

[37]  Todor A Popov,et al.  MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. , 2015, Allergy.

[38]  S. Miller,et al.  The improved efficacy of a fixed‐dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis , 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[39]  P. Matricardi,et al.  The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  E. Meltzer.  Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. , 2013, Allergy and asthma proceedings.

[41]  J. Bousquet,et al.  A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. , 2012, The Journal of allergy and clinical immunology.

[42]  J. Mullol.  Positioning of antihistamines in the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines , 2012 .

[43]  P. Bossuyt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendations , 2011, Allergy.

[44]  A. Salapatek,et al.  Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. , 2011, Allergy and asthma proceedings.

[45]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[46]  F. Hampel,et al.  Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[47]  F. Horak,et al.  The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber , 2010, Inflammation Research.

[48]  P. Patel,et al.  Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? , 2009, Allergy and asthma proceedings.

[49]  J. Bousquet,et al.  Unmet needs in severe chronic upper airway disease (SCUAD). , 2009, The Journal of allergy and clinical immunology.

[50]  G H Guyatt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies , 2009, Allergy.

[51]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations in clinical practice guidelines , 2009, Allergy.

[52]  J. Bousquet,et al.  Implementation of Guidelines for Allergic Rhinitis in Specialist Practices , 2009, International Archives of Allergy and Immunology.

[53]  P. Patel,et al.  Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[54]  S. Kunjibettu,et al.  Onset of Action of Ciclesonide Once Daily in the Treatment of Seasonal Allergic Rhinitis , 2008, Ear, nose, & throat journal.

[55]  P. Roland,et al.  An assessment of the onset and duration of action of olopatadine nasal spray , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[56]  P. Patel,et al.  Onset of Action of Azelastine Nasal Spray Compared with Mometasone Nasal Spray and Placebo in Subjects with Seasonal Allergic Rhinitis Evaluated in an Environmental Exposure Chamber , 2007, American journal of rhinology.

[57]  U. Munzel,et al.  Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy , 2006, Current medical research and opinion.

[58]  F. Horak,et al.  A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC) , 2004, Current medical research and opinion.

[59]  J Bousquet,et al.  Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial , 2003, Allergy.

[60]  A. Harris,et al.  Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. , 2002, The Journal of allergy and clinical immunology.

[61]  R. Naclerio,et al.  Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. , 2001, Archives of internal medicine.

[62]  F. Horak,et al.  Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-release Pseudoephedrine versus Xylometazolin Nasal Spray in Nasal Congestion , 2001, Arzneimittelforschung.

[63]  S. Jäger,et al.  Efficacy and tolerability of astemizole-D and Loratadine-D during prolonged, controlled allergen challenge in the Vienna Challenge Chamber. , 1996, Arzneimittel-Forschung.

[64]  F. Horak,et al.  Onset and Duration of the Effects of Three Antihistamines in Current Use – Astemizole, Loratadine and Terfenadine Forte – Studied during Prolonged, Controlled Allergen Challenges in Volunteers , 1992, The Journal of international medical research.

[65]  Matteo Bonini,et al.  Electronic health (e-Health): emerging role in asthma , 2017, Current opinion in pulmonary medicine.

[66]  J. Bousquet,et al.  MASK-rhinitis, a single tool for integrated care pathways in allergic rhinitis. , 2015, World hospitals and health services : the official journal of the International Hospital Federation.

[67]  E. Arnáiz,et al.  Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[68]  F. Horak,et al.  Efficacy and Safety of an Oral Formulation of Cetirizine and Prolonged-Release Pseudoephedrine versus Budesonide Nasal Spray in the Management of Nasal Congestion in Allergic Rhinitis , 2005, Treatments in respiratory medicine.

[69]  C. Mathers,et al.  WHO Library Cataloguing-in-Publication Data , 2001 .

[70]  F. Horak,et al.  A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. , 1988, Arzneimittel-Forschung.